Rare Cancers – more common than you think
ESMO 2016: Video Hightlights - Sarcoma
More than 4.3 million people in the European Union are affected by rare cancers. Despite the rarity of each of the 198 rare cancers, they represent in total about 22% of all cancer cases, including all cancers in children, diagnosed in the EU28 each year.
Rare Cancers Europe (RCE) is a multi-stakeholder initiative dedicated to putting rare cancers firmly on the European policy agenda and to implementing 39 political and stakeholder recommendations.
-
Rare Cancers: The Challenges
- Late or incorrect diagnosis
- Lack of access to appropriate therapies and clinical expertise
- Very limited number of clinical studies due to the small number of patients -
Specific clinical trial methodology needed for rare cancers
RCE calls for new criteria to be used in clinical trials on rare cancer treatments. Read the full article.
-
Rare Cancers: Pathologic Diagnosis
Rare Cancers Europe Consensus Statement summary on the urgent actions needed to improve pathologic diagnosis of rare cancers.
Read the Statement
Latest News
-
30 Jun 2017
Rare cancer sufferers given reprieve with new drug subsidy
Sufferers of a rare blood cell cancer will get cheap access to a new drug after an unprecedented move by the Australian government.
-
28 Jun 2017
Rare cancers through the looking glass
Despite the rarity of each of the so far 198 types of rare cancers, they account for approximately 22% of all cancer cases diagnosed in EU each year.
-
22 Jun 2017
Male breast cancer is not congruent with the female disease
Differences between breast cancer in men and women are seen in their epidemiological risk factors, molecular profiles and response to systemic therapy.